Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
about
Self-assembling protein nanoparticles in the design of vaccinesReceptor-binding domain-based subunit vaccines against MERS-CoVMiddle East respiratory syndrome: obstacles and prospects for vaccine developmentAnimal models of Middle East respiratory syndrome coronavirus infectionMolecular aspects of MERS-CoV.A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseasePre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infectionOptimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Evaluation of candidate vaccine approaches for MERS-CoV.Development of animal models against emerging coronaviruses: From SARS to MERS coronavirusToward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus.The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Vaccines for the prevention against the threat of MERS-CoV.Middle East respiratory syndrome: current status and future prospects for vaccine development.Vaccines against Middle East respiratory syndrome coronavirus for humans and camels.Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.Immunogenicity and antigenic relationships among spike proteins of porcine epidemic diarrhea virus subtypes G1 and G2.Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike GlycoproteinSanofi Pasteur shows efficacy of its dengue vaccine in phase 3.An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus.Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.MERS-CoV: Understanding the Latest Human Coronavirus Threat.
P2860
Q26767097-CB63FCAE-7B7E-47E1-8BE0-E3C0A9A3E5A4Q26851979-98AA150A-6F54-40AE-98FB-4ABF24C26ACDQ27013314-9D8F6B29-E09F-4864-9EB9-EEA6C5FF0C38Q28086778-52A395A6-CA73-47FA-9E38-B65609F4BDFFQ30234479-E1E1F6F2-3810-4052-BF29-6C3F8EB9AA77Q30378994-FAF2727B-78AA-4F02-B610-F496F9063302Q30400066-2AEEA56B-B98E-446E-AC52-9A0AC15870E9Q34324907-215DF18A-C38F-4B6F-B61E-F77CD9E55AD6Q34468689-96EE9281-59E6-45A4-8D09-7B398BCA9968Q35865538-18FC1BCA-01CF-4458-9FD6-91AA66AE499BQ35887626-4D7CCACC-EA40-4100-BAEB-28DA544F1809Q35917397-237B85E2-96C7-4BC8-BC35-01F1C115E096Q36691163-50DC32C6-732F-4A32-92D9-419BCADFB29AQ37169882-66589593-D35E-49AE-96C3-54A0C2582B3FQ37560824-586B7291-4674-4A66-85A5-C0BF9EE2F7F7Q37706472-E206E3AE-B2C0-419D-9D26-DDCB5C8C4A22Q37717377-4C9BA01D-38D3-46FE-BB30-5B23DD9B1DA6Q38156536-BE0E60C5-FC05-4774-91B4-2F71A2125B17Q38388047-D18A60AC-C268-4B5E-A48C-291D93FA58B5Q38778044-49DDCF6F-EF2A-4B4F-A4C6-5213744E19DCQ38959242-3C3A5959-158F-4CA2-8C10-693AF5B31796Q38992327-D1AF7B04-69AF-4573-89D1-EBA3A6923BBCQ39102732-9F0C5448-E46D-4B73-8053-E7B0845E859DQ40317741-B6A1B2B0-F23F-4665-B5D0-23EE4939D070Q40787125-26853E25-EDD7-4CF3-95EF-75929A346952Q40892893-4C9952C1-70C8-41FA-B2E3-102372D1CD87Q41199088-1DE23E04-66E2-4D9C-BFB6-CEF2832BDA26Q42361450-FF089958-20F3-463F-A2FC-550510CA41DEQ47132991-41A4F271-F314-4B29-A83A-E4C680C956FAQ47607374-1752231E-559D-4010-89CA-C8BCDD78C4F4Q47656792-E6488099-F8E5-4ACB-A1B3-B7C317900116Q53701486-5C1423B7-4D0B-4260-B0EE-328FA0BB5A47
P2860
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Purified coronavirus spike pro ...... utralizing antibodies in mice.
@en
type
label
Purified coronavirus spike pro ...... utralizing antibodies in mice.
@en
prefLabel
Purified coronavirus spike pro ...... utralizing antibodies in mice.
@en
P2093
P2860
P1433
P1476
Purified coronavirus spike pro ...... utralizing antibodies in mice.
@en
P2093
David C Flyer
Gale E Smith
Justin K Taylor
Matthew B Frieman
Michael Massare
P2860
P304
P356
10.1016/J.VACCINE.2014.04.016
P407
P577
2014-04-13T00:00:00Z